Free Trial

Privia Health Group (PRVA) Stock Forecast & Price Target

Privia Health Group logo
$21.56 +0.48 (+2.28%)
(As of 11/22/2024 ET)

Privia Health Group - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
14

Based on 16 Wall Street analysts who have issued ratings for Privia Health Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 16 analysts, 2 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for PRVA.

Consensus Price Target

$25.07
16.26% Upside
According to the 16 analysts' twelve-month price targets for Privia Health Group, the average price target is $25.07. The highest price target for PRVA is $30.00, while the lowest price target for PRVA is $20.00. The average price target represents a forecasted upside of 16.26% from the current price of $21.56.
Get the Latest News and Ratings for PRVA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Privia Health Group and its competitors.

Sign Up

PRVA Analyst Ratings Over Time

TypeCurrent Forecast
11/26/23 to 11/25/24
1 Month Ago
10/27/23 to 10/26/24
3 Months Ago
8/28/23 to 8/27/24
1 Year Ago
11/26/22 to 11/26/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$25.07$24.73$24.86$34.64
Forecasted Upside16.26% Upside40.13% Upside19.74% Upside53.94% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Buy

PRVA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PRVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Privia Health Group Stock vs. The Competition

TypePrivia Health GroupMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside16.26% Upside27,047.33% Upside7.66% Upside
News Sentiment Rating
Positive News

See Recent PRVA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/8/2024Barclays
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$19.00 ➝ $21.00-3.49%
11/8/2024Truist Financial
2 of 5 stars
 Boost TargetBuy ➝ Buy$24.00 ➝ $27.00+20.48%
10/11/2024KeyCorp
3 of 5 stars
 Initiated CoverageOverweight$23.00+34.35%
8/26/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$23.00 ➝ $24.00+15.05%
8/14/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$28.00 ➝ $28.00+44.26%
7/9/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$23.00 ➝ $20.00+18.69%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/10/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$37.00 ➝ $26.00+44.36%
5/1/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$28.00 ➝ $24.00+30.43%
4/22/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$25.00+38.27%
3/6/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$38.00 ➝ $30.00+41.38%
3/1/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$31.00 ➝ $29.00+31.28%
3/1/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$30.00 ➝ $26.00+16.49%
2/26/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$33.00 ➝ $25.00+25.63%
2/22/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$27.00 ➝ $21.00+2.79%
12/6/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$27.00+29.19%
5/5/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$39.00 ➝ $40.00+38.70%
4/11/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$33.00+17.61%
3/7/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$41.00+44.26%
2/3/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$32.00+15.52%
1/9/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$45.00 ➝ $40.00+85.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:53 AM ET.


PRVA Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Privia Health Group is $25.07, with a high forecast of $30.00 and a low forecast of $20.00.

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Privia Health Group in the last year. There are currently 2 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRVA shares.

According to analysts, Privia Health Group's stock has a predicted upside of 16.26% based on their 12-month stock forecasts.

Over the previous 90 days, Privia Health Group's stock had 1 upgrade by analysts.

Privia Health Group has been rated by research analysts at Barclays, KeyCorp, and Truist Financial in the past 90 days.

Analysts like Privia Health Group more than other "medical" companies. The consensus rating for Privia Health Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PRVA compares to other companies.


This page (NASDAQ:PRVA) was last updated on 11/25/2024 by MarketBeat.com Staff
From Our Partners